

In the claims:

Please cancel claims 30 and 31.

Please amend claims 27-29 and 57 as follows:

27. (Amended) An eukaryotic expression vector, comprising a nucleic acid encoding full length human serum transferrin linked to appropriate genetic regulatory elements for expression in an eukaryotic cell.

28. (Amended) An eukaryotic expression vector, comprising a nucleic acid encoding a human serum transferrin C-terminal lobe ~~half~~ molecule comprising at least the binding domain of a single lobe of transferrin linked to appropriate genetic regulatory elements for expression in an eukaryotic cell.

29. (Amended) An eukaryotic expression of vector of claim 27 or 28, wherein the vector includes a nucleic acid encoding transferrin signal sequence linked to the nucleic acid encoding the transferrin or transferrin C-terminal lobe ~~half~~ molecule.

57. (Amended) A method of producing functionally active full length human transferrin, or a C-terminal portion or mutant thereof, comprising:

- a) culturing the eukaryotic cell of claim 55, under conditions conducive to expression of the encoded transferrin; and
- b) recovering the expressed transferrin.

REMARKS***Status of the Claims***

Applicants gratefully acknowledge the indication of allowability of claims 32-37 and 41-54. Claims 30 and 31 have been canceled. Claims 27-29 and 57 have been amended. Accordingly, claims 27-29 and 32-60 are currently pending in the application.

Support for the amended claims can be found in the specification as originally filed. Support for the amendment to claim 27 can be found at least, for example, on page 16, lines 32-39, and page 17, lines 1-8. Support for the amendment to claim 28 can be found at least, for example, on page 16, lines 16-29. Support for the amendment to claim

See
Appendix B